Engineered immune cells plus chickenpox vaccine take on childhood cancers
NCT ID NCT01953900
First seen Jan 30, 2026 · Last updated May 01, 2026 · Updated 17 times
Summary
This early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapy. It combines specially engineered immune cells (GD2-CAR T cells) with a chickenpox vaccine to help the cells last longer in the body. The main goals are to find a safe dose and see if the treatment can shrink tumors. About 26 participants will receive the cells after chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.